Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Gina Ma, Yi Wang, Tahmeena Ahmed, Ann Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Shafic Salman

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

Original languageEnglish (US)
Pages (from-to)42-44
Number of pages3
JournalLeukemia Research Reports
Volume9
DOIs
Publication statusPublished - 2018

    Fingerprint

Keywords

  • Acute myeloid leukemia
  • Chimeric antigen receptors
  • Immunotherapy
  • Mixed phenotype acute leukemia
  • T cells

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ma, G., Wang, Y., Ahmed, T., Zaslav, A. L., Hogan, L., Avila, C., ... Salman, H. S. (2018). Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia. Leukemia Research Reports, 9, 42-44. https://doi.org/10.1016/j.lrr.2018.03.002